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Abstract
Background: Squamous cell carcinoma of the oral cavity (OSCC) is a common cancer form with relatively low 5-year
survival rates, due partially to late detection and lack of complementary molecular markers as targets for treatment.
Molecular profiling of head and neck cancer has revealed biological similarities with basal-like breast and lung
carcinoma. Recently, we showed that 16 genes were consistently altered in invasive breast tumors displaying
varying degrees of aggressiveness.
Methods: To extend our findings from breast cancer to another cancer type with similar characteristics, we performed
an integrative analysis of transcriptomic and proteomic data to evaluate the prognostic significance of the 16 putative
breast cancer-related biomarkers in OSCC using independent microarray datasets and immunohistochemistry.
Predictive models for disease-specific (DSS) and/or overall survival (OS) were calculated for each marker using
Cox proportional hazards models.
Results: We found that CBX2, SCUBE2, and STK32B protein expression were associated with important
clinicopathological features for OSCC (peritumoral inflammatory infiltration, metastatic spread to the cervical
lymph nodes, and tumor size). Consequently, SCUBE2 and STK32B are involved in the hedgehog signaling
pathway which plays a pivotal role in metastasis and angiogenesis in cancer. In addition, CNTNAP2 and S100A8
protein expression were correlated with DSS and OS, respectively.
Conclusions: Taken together, these candidates and the hedgehog signaling pathway may be putative targets
for drug development and clinical management of OSCC patients.
Keywords: Oral squamous cell carcinoma, Outcome prediction, Molecular biomarker, Immunohistochemistry,
Model validation
Background
Oral squamous cell carcinoma (OSCC) is the most com-
mon malignancy form in the head and neck region, ac-
counting for about 260,000 new cases and 124,000
OSCC-related deaths worldwide annually [1,2]. In west-
ern countries, the etiology of some newly diagnosed
primary SCCs of the head and neck has shifted from to-
bacco and alcohol abuse to human papillomavirus (HPV)
infections, possibly as a result of changes in sexual prac-
tices [3-8]. Despite aggressive treatment modalities, 5-year
survival rates for advanced head and neck cancers have
remained low and relatively unchanged (about 50-60%)
for several decades, partially due to early locoregional re-
currences within 2 years of initial treatment [9]. There is
therefore a pressing need for molecular predictors that en-
able earlier detection of the disease, describe tumor behav-
ior, and improve risk assessment to identify patients at
risk for recurrence and OSCC-related death.
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ive method for cancer gene discovery and classification
of cancer. Almost a decade ago, Chung et al. identified
four intrinsic subtypes for head and neck squamous cell
carcinoma with clinical and biological implications [10].
Consequently, one of the subtypes with the most un-
favorable prognosis also displayed strikingly similar tran-
scriptional patterns with the breast carcinoma basal-like
phenotype and lung squamous cell carcinoma. Recently,
additional evidence of shared cellular processes was found
between breast carcinoma and oral squamous cell carcin-
oma, i.e. mechanisms for tumor lymphangiogenesis and
metastasis to the regional lymph nodes as well as HER2/
neu polymorphisms [11,12]. These findings suggest that
cancers derived from different sites of origin may perturb
common signaling pathways and thereby display similar
tumor characteristics [13]. To test this hypothesis, we eval-
uated the prognostic potential of 16 putative prognostic
biomarkers (AZGP1, BTG2, CBX2, CNTNAP2, DNALI1,
LOC389033, NME5, PIP, S100A8, SCUBE2, SERPINA11,
STC2, STK32B, SUSD3, UBE2C,a n dWHSC1L1)p r e v i -
ously identified in breast carcinoma using oral squamous
cell carcinoma [14,15]. Interestingly, several of the putative
biomarkers have been implicated in the carcinogenesis of
more than one cancer form. We, and others, have also been
able to show that AZGP1, S100A8,a n dSTK32B,a sw e l la s
CNTNAP2 are associated with the basal-like phenotype
and lymph node metastasis, respectively [15-17].
Here, we investigated the prognostic potential of the
gene expression signature in relation to clinical outcome,
disease-specific survival (DSS) and/or overall survival
(OS), in two steps. First, transcriptional levels for each
gene were evaluated with respect to the clinical endpoints
using publicly available Affymetrix one-channel micro-
array (n=168) and Illumina RNASeq datasets (n=198)
for OSCC from the Gene Expression Omnibus (GEO) and
The Cancer Genome Atlas (TCGA) repositories, respect-
ively. Second, because correlation between mRNA/protein
levels is frequently low, Cox proportional hazards models
for DSS and OS were also calculated using immunohisto-
chemical protein expression patterns from 43 OSCC cases
together with established clinicopathological features
(tumor size and node status or tumor size and age,
respectively).
Methods
Patient cohorts
To evaluate the prognostic potential of the AZGP1, BTG2,
CBX2, CNTNAP2, DNALI1, LOC389033, NME5, PIP,
S100A8, SCUBE2, SERPINA11, STC2, SUSD3, STK32B,
UBE2C,a n dWHSC1L1 genes in OSCC specimens, three
patient cohorts were compiled primarily from squamous
cell carcinomas of the oral cavity. External gene expres-
sion datasets and corresponding clinical information for
Cohorts I-II were compiled from the Gene Expression
Omnibus (GEO) and The Cancer Genome Atlas (TCGA)
repositories, respectively. Cohort I included two Affyme-
trix U133 Plus 2.0 GeneChip datasets (GEO accession
numbers GSE41613 and GSE42743) containing 168 OSCC
samples (oropharynx samples were excluded from the ana-
lysis) [18]. Cohort II consisted of normalized RNAseq by
Expectation-Maximization (RSEM) gene datasets from 198
OSCC patients (oral cavity: buccal mucosa, floor of
mouth, tongue), which were downloaded from The Broad
Institute TCGA GDAC (http://gdac.broadinstitute.org/
runs/stddata__2014_01_15/). Cohort III consisted of
43 OSCC cases originating from the oral cavity (buccal
gingiva, floor of mouth, tongue), which had been diag-
nosed between 1997-2004 at Sahlgrenska University
Hospital in Gothenburg, Sweden. All patients under-
went diagnostic battery inclusive biopsy of the primary
tumor, palpation of the neck, radiological examination
with MRT and/or CT, and TNM classified according to
the American Joint Committee on Cancer (AJCC) sta-
ging system. Surgical excision of the primary tumor
and supraomohyoid neck dissection (SOHND) were
performed. In total, 16 patients had cervical lymph
node metastases (pN1) of which 5/16 patients had
micrometastases (pNmic) as assessed using anti-human
monoclonal cytokeratin AE1/AE3, and 27 patients were
lymph node-negative (pN0). Lymph node-positive patients
received post-operative radiotherapy to the neck, whereas
pN0 and pNmic patients were followed up clinically. All
patients were followed up for at least five years during
which seven patients (16%) developed local and/or re-
gional recurrence, including two patients with pN1, three
patients with pNmic, and two patients with pN0 disease.
Three of the five patients with micrometastases developed
recurrence (60%), of which two (40%) died within three
years due to OSCC-related causes. The clinicopathological
features for Cohorts I-III are summarized in Table 1.
Immunohistochemistry
For Cohort III, 45 FFPE samples corresponding to the
43 patients were obtained from the Department of Path-
ology at Sahlgrenska University Hospital and used in im-
munohistochemistry experiments in accordance with the
Declaration of Helsinki and approved by the Medical Fac-
ulty Research Ethics Committee (Gothenburg, Sweden).
The ethics committee approved a waiver of written con-
sent to use the tumor specimens in the study. Histological
classification and TNM staging of the tumor specimens
were performed according to the WHO classification and
International Union Against Cancer (UICC), respectively
[19,20]. Optimal antibody dilutions and assay conditions
were achieved for immunohistochemistry using OSCC as
positive controls. Four micrometer full-face FFPE sections
were pretreated using the Dako PTLink system (Dako,
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vision™ FLEX High pH Link Kit (pH 9) for p16, AZGP1,
BTG2, CBX2, CNTNAP2, NME5, S100A8, SCUBE2,
SERPINA11, STC2, SUSD3, STK32B, SUSD3, UBE2C,
and WHSC1L1 as listed in Additional file 1: Table S1.
Peroxidase-catalyzed diaminobenzidine was used as the
chromogen, followed by hematoxylin counterstain. The
slides were then rinsed with deionized water, dehydrated
in absolute alcohol, followed by 95% alcohol, cleared in
xylene, and mounted. H & E staining was performed on
one FFPE section to facilitate histological assessment. The
degree of lymphoplasmacytic infiltration (inflammatory
infiltration) was classified as minimal (few inflammatory
cells), moderate (1-2 mm margin), and strong (>2 mm
margin) according to the density of inflammatory cells.
Immunostaining was evaluated by a head and neck
pathologist, blinded to patient clinical outcome, and
scored as previously described using the semi-quantitative
H-score method to calculate the sum of the percentage
and intensity of positively stained tumor cells within the in-
vasive tissue component (negative staining=0; weak stain-
ing=1+; moderate staining =2+; strong staining =3+).
The H-score ranged from 0 to 300, where H-score=
(1 ×%1+)+ (2 ×%2+)+ (3 ×%3+) [21]. The X-tile soft-
ware (version 3.6.1) was used to determine an H-score
cut-off for positive staining by dichotomizing patients ac-
cording to H-score value and clinical outcome, as listed in
Additional file 1: Table S1 [22]. FFPE specimens lacking
an invasive tissue component were removed from the ana-
lysis. Each tumor specimen was scored once, where mul-
tiple FFPE sections representing the same tumor were
averaged. Staining was evaluated in the invasive and peri-
tumoral stromal/normal tissue components.
Statistical analysis
Statistical analyses were performed using a 0.05 P-value
cutoff (two-sided) in R/Bioconductor (version 2.15.0).
Putative prognostic biomarkers for OSCC were identified
in two steps. First, the prognostic potential of aberrant
biomarker gene expression was evaluated in external
microarray and RNASeq datasets (Cohorts I-II). Then,
predictive models for DSS and OS were developed
using biomarker protein expression (Cohort III).
Table 1 Clinicopathological features for OSCC patients in
Cohorts I-III
Cohort I†
(n= 168)
Cohort II‡
(n= 198)
Cohort III*
(n=43)
Age (y)
19-39 13 (8%) 11 (6%) 2 (5%)
40-49 29 (17%) 24 (12%) 4 (9%)
50-59 43 (26%) 50 (25%) 12 (28%)
60-88 83 (49%) 113 (57%) 25 (58%)
Not available 0 (0%) 0 (0%) 0 (0%)
Sex
Female 47 (28%) 68 (34%) 20 (47%)
Male 121 (72%) 130 (66%) 23 (53%)
Not available 0 (0%) 0 (0%) 0 (0%)
Tumor site
Oral cavity 71 (42%) 198 (100%) 43 (100%)
Not available 97 (58%) 0 (0%) 0 (0%)
Cervical lymph node status
pN0 0 (0%) 70 (35%) 27 (63%)
pN1 0 (0%) 98 (50%) 16 (37%)
Not available 168 (100%) 30 (15%) 0 (0%)
Tumor size
T1-T2 30 (18%) 83 (42%) 36 (84%)
T3-T4 41 (24%) 111 (56%) 7 (16%)
Not available 97 (58%) 4 (2%) 0 (0%)
Clinical stage
I/II 71 (42%) 61 (31%) 25 (58%)
III/IV 97 (58%) 133 (67%) 18 (42%)
Not available 0 (0%) 4 (2%) 0 (0%)
Differentiation
Well 0 (0%) 30 (15%) 12 (30%)
Moderate 0 (0%) 128 (65%) 22 (51%)
Poor 0 (0%) 38 (19%) 7 (16%)
Not available 168 (100%) 2 (1%) 0 (0%)
Tumor inflammatory
infiltration
Minimal 0 (0%) 0 (0%) 13 (30%)
Moderate 0 (0%) 0 (0%) 13 (30%)
Strong 0 (0%) 0 (0%) 16 (37%)
Not available 168 (100%) 198 (100%) 0 (0%)
Tobacco smoking
history
Never smoker 15 (9%) 46 (23%) 18 (42%)
Former smoker 28 (17%) 87 (44%) 5 (12%)
Current smoker 28 (17%) 57 (29%) 12 (28%)
Chewing tobacco 0 (0%) 0 (0%) 1 (2%)
Not available 97 (58%) 8 (4%) 7 (16%)
Table 1 Clinicopathological features for OSCC patients in
Cohorts I-III (Continued)
p16
Negative 97 (58%) 0 (0%) 35 (81%)
Positive 0 (0%) 0 (0%) 8 (19%)
Not available 71 (42%) 198 (100%) 0 (0%)
†Gene Expression Omnibus (GEO) accession numbers GSE41613
and GSE42743.
‡HNSC The Cancer Genome Atlas (TCGA) data.
*FFPE samples from Sahlgrenska University Hospital, Gothenburg, Sweden.
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signature in external microarray and RNASeq datasets
Univariate Cox proportional hazard models were calcu-
lated for each gene using the endpoints disease specific-
survival (DSS) and/or overall survival (OS). OSCC survival
rates were defined as a) the period from initial diagnosis
to OSCC-related death for DSS and b) period from initial
diagnosis to death from any cause for OS. Data processing
and Cox regression analysis of the Affymetrix one-channel
microarray datasets (Cohort I) and normalized RNASeq
RSEM values (Cohort II) were performed using Nexus Ex-
pression 3.0 (BioDiscovery).
Development of a predictive model for DSS and OS using
protein expression
Survival rates (DSS and OS) at different protein expres-
sion levels were depicted with Kaplan-Meier curves and
tested with log-rank test. The relationship between clini-
copathological features and protein expression was eval-
uated using two-tailed Fisher’s exact test. Multivariate
analysis was conducted using the Cox proportional haz-
ard model for DSS or OS with stepwise selection to as-
sess the predictive strength and additive accuracy of
protein expression after adjusting for established clinico-
pathological features (tumor size and node status or
tumor size and age, respectively). A concordance index
(C-index) for the time-dependent area under the ROC
curve (AUC (t)) was calculated to assess model predictive
performance, varying from C-index=0.5 (no predictive
power) to C-index=1 (perfect prediction).
Results
Prognostic potential of the molecular biomarkers in
external gene expression microarray and RNASeq
datasets
In previous work, we showed the clinical significance of 16
candidate molecular biomarkers (AZGP1, BTG2, CBX2,
CNTNAP2, DNALI1, LOC389033, NME5, PIP, S100A8,
SCUBE2, SERPINA11, STC2, STK32B, SUSD3, UBE2C,
and WHSC1L1) in invasive breast carcinoma [14,15,23].
To investigate whether these putative prognostic bio-
markers may also play a pivotal role in the aggressive
nature of OSCCs, the effect of altered gene expression
patterns on clinical outcome was evaluated using two
external OSCC patient cohorts (Cohorts I-II; Table 1).
Cox proportional hazard models were calculated for
each gene with relation to clinical endpoints (DSS and/
or OS; Table 2).
In Cohort I, two genes (LOC389033 and SERPINA11)
were not found on the Affymetrix platform and therefore
excluded from the analysis. Univariate Cox regression ana-
lysis showed that low levels of AZGP1 (P=0. 00 1) ,BTG2
(P=0. 02 0) ,PIP (P=0.010), and SCUBE2 (P=0. 02 6)we re
indicative of a more unfavorable prognosis, whereas ele-
vated levels of STC2 (P=0. 00 1) an d UBE2C (P=0. 04 2)
had an adverse effect on DSS. For OS, low levels of BTG2
Table 2 Univariate Cox proportional hazard regression models for OSCC Cohorts I-II
Cohort I (n=168) Cohort II (n=198)
Disease-specific survival Overall survival Overall survival
No. Variables Coefficient p-value Coefficient p-value Coefficient p-value
1 AZGP1 -0.210 0.001 -0.058 0.151 -0.020 0.632
2 BTG2 -0.651 0.020 -0.597 0.005 -0.036 0.807
3 CBX2 0.334 0.313 0.690 0.005 0.061 0.591
4 CNTNAP2 0.225 0.389 0.262 0.176 -0.003 0.938
5 DNALI1 -0.348 0.617 -0.246 0.638 -0.077 0.429
6 LOC389033 ND ND ND ND -0.464 0.142
7 NME5 -0.302 0.477 0.299 0.323 0.225 0.050
8 PIP -0.242 0.010 -0.003 0.948 -0.009 0.871
9 S100A8 -0.125 0.125 -0.121 0.053 -0.103 0.072
10 SCUBE2 -0.625 0.026 -0.250 0.195 -0.130 0.067
11 SERPINA11 ND ND ND ND -0.036 0.625
12 STC2 0.561 0.001 0.459 0.001 0.082 0.379
13 STK32B 0.488 0.303 0.850 0.015 -0.038 0.612
14 SUSD3 1.448 0.080 1.092 0.088 0.050 0.613
15 UBE2C 0.279 0.042 0.166 0.107 0.388 0.005
16 WHSC1L1 -0.266 0.368 0.014 0.942 0.010 0.949
Statistically significant variables (p < 0.05) are displayed in bold text.
Abbreviation: ND Not determined.
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(P=0. 00 1) ,a n dSTK32B (P= 0.015) were predictive of out-
come. In addition, low S100A8 mRNA levels (P= 0.053)
were borderline significant for OS.
For Cohort II, the 16-gene signature was evaluated in
RNASeq expression profiling data for 198 OSCC pa-
tients. Univariate Cox regression analysis showed that el-
evated levels of UBE2C mRNA levels (P= 0.005) were
indicative of OS. On the other hand, elevated levels of
NME5 (P= 0.050), low S100A8 levels (P =0.072), and
low SCUBE2 levels (P =0.067) were borderline signifi-
cant for OS. Furthermore, low S100A8 levels (P <0.001;
log2ratio = -2.61) and elevated UBE2C levels (P= 0.007;
log2ratio = 0.713) were significantly associated with high
histological grade.
Protein expression levels of the molecular biomarkers in
OSCC specimens
Protein expression levels for the candidate biomarkers
were evaluated using immunohistochemistry with 45
full-face FFPE specimens representing 43 OSCC pa-
tients (Cohort III; Table 1). PIP and DNALI1 were ex-
cluded from further analysis due to low expression
levels in OSCC samples, whereas LOC389033 was ex-
cluded because the gene is not expressed at the protein
level. Immunopositivity was shown for all of the exam-
ined proteins in peritumoral normal mucous membrane,
the salivary glands, and dysplasia, with the exception of
AZGP1, SUSD3, UBE2C, and WHSC1L1. AZGP1 and
UBE2C were strongly positive in the basal cell layer;
SUSD3 was positive in the mucous membrane but nega-
tive in the salivary glands, whereas WHSC1L1-positivity
was shown in the layers of muscle tissue. In addition, no
S100A8 staining was observed in the basal cell layer. In in-
vasive tissue, immunopositivity for the 14 analyzed pro-
teins ranged from 14-86% with CNTNAP2 and WHSC1L1
having the lowest and highest incidence rates, respectively
(Table 3). Interestingly, there was only one reported case
(6%) of SCUBE2-positivity in lymph node-positive tumors,
compared with SCUBE2-positivity in 41% of lymph node-
negative tumors. In addition, p16 immunopositivity was
observed in 8/43 tumor specimens (19%).
Correlation of the molecular biomarkers with
clinicopathological features
To investigate whether heterogeneous protein expression
of the analyzed antigens is clinically relevant, a correlation
analysis was performed with established clinicopathologi-
cal features (Additional file 2: Table S2). S100A8 was
strongly associated with tumor differentiation (P=0.00 9) ,
e.g. tumors with enhanced S100A8 expression levels were
frequently well differentiated (64%) compared with 17% in
S100A8-negative tumors. In addition, SCUBE2 was signifi-
cantly associated with lymph node status (P=0.01 ),CB X2
with tumor inflammatory infiltration (P =0.03), and
STK32B with tumor size (P=0.04). Interestingly, a high
proportion of SCUBE2-positive tumors (11/12) were
lymph node-negative and all STK32B-positive tumors
(15/15) were smaller in size (T1-T2 tumors); minimal
peritumoral inflammatory infiltration was found in tu-
mors with reduced CBX2 levels. Additionally, we also
found a slight indication that UBE2C and SCUBE2,
SERPINA11, and NME5 were associated with tumor
differentiation (P =0.06 and P =0.09, respectively), in-
flammatory infiltration (P = 0.09), and p16 expression
(P =0.08), respectively.
Prognostic significance of the molecular biomarkers
Next, we examined the prognostic significance of the
proposed biomarkers using disease-specific survival and
overall survival. OSCC patients with tumors displaying
enhanced CNTNAP2 levels had significantly shorter DSS
(P= 0.010; HR (95% CI) = 5.70 (1.27-25.57)), whereas pa-
tients with S100A8-negative tumors had significantly
shorter OS (P=0.0063; HR (95% CI)=0.10 (0.014-0.76);
Figure 1). Our data suggest a slight association between
SCUBE2 expression and DSS (P =0.090), as well as
UBE2C expression and OS (P=0.074). CNTNAP2 ex-
pression had no significant effect on DSS after adjusting
for tumor size and lymph node status (P=0.10 - HR (95%
CI)=3.56 (0.78-16.17)). Furthermore, outcome prediction
was not improved using a predictive model for DSS in-
cluding CNTNAP2 expression, lymph node status, and
tumor size (C-index=0.949) compared with a model con-
taining lymph node status and tumor size (C-index=
0.941; Figure 2). Following multivariate analysis adjusting
Table 3 Incidence of molecular marker immunopositivity
in OSCC (Cohort III)
Biomarker Total patients
(n=43)
Lymph
node-positive
(n= 16)
Lymph
node-negative
(n=27)
AZGP1 cytoplasmic 31 (72%) 12 (75%) 19 (70%)
AZGP1 nuclear 25 (58%) 11 (69%) 14 (52%)
BTG2 16 (37%) 7 (44%) 9 (33%)
CBX2 33 (77%) 15 (94%) 18 (67%)
CNTNAP2 6 (14%) 4 (25%) 2 (7%)
NME5 12 (28%) 6 (38%) 6 (22%)
S100A8 11 (26%) 3 (19%) 8 (30%)
SCUBE2 12 (28%) 1 (6%) 11 (41%)
SERPINA11 17 (40%) 7 (44%) 10 (37%)
STC2 20 (47%) 7 (44%) 13 (48%)
STK32B 15 (35%) 4 (25%) 11 (41%)
SUSD3 25 (58%) 9 (56%) 16 (59%)
UBE2C 8 (19%) 3 (19%) 5 (19%)
WHSC1L1 37 (86%) 14 (88%) 23 (85%)
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S100A8 was still statistically significant (P=0. 01 3 - HR
(95% CI)=0.11 (0.013-0.92; Table 4)). Combining S100A8
in a predictive model for OS with tumor size, lymph node
status, differentiation and age improved outcome predic-
tion significantly from 0.605 to 0.833 (Figure 2).
Discussion
Oral squamous cell carcinoma is a heterogeneous dis-
ease with diverse clinical, pathological, and biological be-
havior [10]. Nevertheless, the strongest determinants of
prognosis still include tumor stage and the presence of
cervical metastases at the time of diagnosis, as well as
the time to locoregional recurrences [9,24-26]. Unfortu-
nately, up to 50% of OSCCs are diagnosed at an advanced
stage with 5-year survival rates at approximately 60%, e.g.
delayed diagnosis [27-30]. Therefore, many patients could
benefit greatly from complementary molecular markers,
which may help guide treatment decisions and be of value
in the development of new therapeutic agents. Extensive
efforts are currently being made to identify and validate
biomarkers based on the biology of oral cancers that can
complement established clinicopathological features and
improve clinical management of the disease. Recent work
to characterize OSCC using transcriptomic profiling has
mainly focused on the identification of biomarkers for dis-
ease progression and lymph node metastasis prediction
[31-38]. Surprisingly, few gene expression signatures
have been developed to improve patient risk assess-
ment [18,34,39,40]. Although transcriptome analyses
Figure 1 Prognostic potential of CNTNAP2 and S100A8 protein expression in OSCC. (A-B) Kaplan-Meier estimates of the probability of
disease-specific survival and overall survival according to dichotomized protein expression for CNTNAP2 and S100A8, respectively. Patients with
CNTNAP2-positive and S100A8-negative tumors had significantly shorter survival times. P-values, hazard ratios (HR), and 95% confidence intervals
(95% CI) were calculated using the log-rank test and Cox proportional hazards regression, respectively. The x-axes depict Months after initial diagnosis
and the y-axes depict Disease-specific survival or Overall survival. (C) Representative immunohistochemical staining showing protein expression
patterns in the invasive tissue component.
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mRNA and protein levels may not correlate because gene
expression is controlled by a multistage system. We have
therefore performed immunohistochemistry using readily
available FFPE samples to evaluate the clinical significance
of the 16 putative biomarkers in OSCC. Here, we show
the prognostic potential of the S100A8 and CNTNAP2
proteins, as well as the relationship between SCUBE2,
CBX2, and STK32B protein levels and important clinico-
pathological features for OSCC, i.e. regional metastasis to
the cervical lymph nodes, tumor inflammatory infiltration,
and tumor size, respectively.
In the present work, we evaluated the applicability of
breast cancer prognostic biomarkers for OSCC, given
the biological similiarities between the two cancer types
[10]. In breast carcinoma, we showed the recurrent up-
regulation of the CBX2, CNTNAP2, S100A8, UBE2C,a n d
WHSC1L1 genes as well as downregulation of the AZGP1,
BTG2, DNALI1, LOC389033, NME5, PIP, SCUBE2, SER-
PINA11, STC2, STK32B,a n dSUSD3 genes in more ag-
gressive tumors [14,15,23]. The prognostic potential of
individual biomarkers in the 16-gene signature were eval-
uated in three OSCC patient cohorts containing clinical
information, two of which (Cohorts I-II) were compiled
from publicly available Affymetrix and Illumina RNASeq
datasets. The Affymetrix one-channel system and Illumina
RNAseq platform have recently been shown to correlate
well, in particular for high abundance genes [41]. Al-
though the majority of the markers in the signature were
in agreement for both breast carcinoma and OSCC, five
proteins (S100A8, STC2, STK32B, SUSD3, and WHSC1L1)
were inversely regulated in aggressive OSCC samples. In
addition, several of the biomarkers which showed promise
at the mRNA level (CBX2, S100A8, SCUBE2,a n dSTK32B)
were also either predictive of clinical outcome or associated
with clinicopathological features at the protein level. The
differences in the prognostic potential of specific bio-
markers at the mRNA or protein levels may possibly be
the result of small sample sizes, discordant mRNA-protein
expression patterns or differences in sample prepar-
ation for microarray analyses and immunohistochemis-
try, i.e. microarray is frequently performed using a
tumor mass, which consists of both malignant and
nonmalignant cells, resulting in an over- or underesti-
mation of expression levels, whereas cell type-specific
protein expression patterns can be easily interpreted
using immunohistochemistry. In breast carcinoma, ele-
vated levels of the S100A8 protein were associated with
moderate/strong tumor inflammatory infiltration and sig-
nificantly shorter DSS rates. In contrast, lower S100A8
protein levels were associated with significantly shorter
OS rates in OSCC, but there was no association with
tumor infiltration. These findings suggest differences in
cell type-specific gene expression and thereby activation
Figure 2 Predictive performance of prognostic models including CNTNAP2 or S100A8. (A) The lines represent the time-dependent area
under the ROC curve (AUC (t)) for disease-specific survival using established clinical variables (lymph node status and tumor size) assessed
individually and in conjunction with CNTNAP2 protein expression. The estimated performance of the model including CNTNAP2 was
marginally better than the model containing the established clinical variables alone, increasing the C-index from 0.941 to 0.949. (B) The
lines represent the time-dependent area under the ROC curve (AUC (t)) for overall survival using established clinical variables (lymph
node status, tumor size, differentiation, age) assessed individually and in conjunction with S100A8 protein expression. Combining the
established clinical variables with S100A8 protein expression increased the C-index significantly from 0.605 to 0.833. The x-axes depict
Survival time in months and the y-axes depict AUC (t).
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http://www.biomedcentral.com/1471-2407/14/324and/or inhibition of diverse cellular mechanisms. Further-
more, CBX2, CNTNAP2, S100A8, SCUBE2, and STK32B
protein levels were significantly associated with estab-
lished clinicopathological features for OSCC and/or patient
clinical outcome. We propose here two potential prognos-
tic biomarkers for OSCC (the CNTNAP2 protein for DSS
and the S100A8 protein for OS). There may be several rea-
sons why these candidate biomarkers were associated with
different clinical endpoints: differences in gene function
and whether the biomarkers correlated with strong deter-
minants of OSCC-related prognosis, e.g. tumor stage,
lymph node metastasis or time to locoregional recurrences.
Chen et al. identified upregulation of CNTNAP2 mRNA
levels as a distinctive characteristic of OSCC in comparison
with normal mucosa [32]. In a genome-wide association
study for oral cancers, CNTNAP2 was found to be associ-
ated with cell migration [42]. The CNTNAP2 gene also
functions as a cell adhesion molecule and has been found
to be either methylated or deleted in several different can-
cer types, e.g. glioma, myleoid leukemia, and pancreatic
adenocarcinoma [43-45]. In the present study, elevated
CNTNAP2 protein levels were prevalent in tumors from
pN1 patients, but this association was not statistically sig-
nificant likely due to the low number of events. These find-
ings and the known function of the CNTNAP2 protein in
tumorigenesis suggest that it may be a determinant of
metastatic spread to the cervical lymph nodes and thereby
a more aggressive phenotype with an adverse effect on DSS.
Although elevated CNTNAP2 levels were predictive of a
more unfavorable prognosis in univariate Cox regression
Table 4 Univariate and multivariate survival analysis for disease-specific and overall survival in OSCC (Cohort III)
Univariate analysis
Disease-specific survival Overall survival
Variable HR (95% CI) p-value C-index HR (95% CI) p-value C-index
Age 1.02 (0.96-1.08) 0.58 0.56 1.05 (1.01-1.09) 0.02 0.67
Tumor site - 0.24 0.67 0.92 (0.31-2.68) 0.87 0.53
Tumor size 31.59 (1.57-633.64) 0 0.66 15.93 (1.41-179.93) 0.02 0.58
Node status - 0 0.84 2.96 (1.19-7.39) 0.02 0.64
Differentiation - 0.11 0.73 0.95 (0.17-5.18) 0.11 0.63
Tumor inflammatory infiltration 3.91 (0.46-33.48) 0.20 0.67 0.91 (0.31-2.72) 0.99 0.51
p16 0.62 (0.074-5.16) 0.65 0.53 0.69 (0.20-2.36) 0.55 0.53
AZGP1 cytoplasmic 0.95 (0.18-4.87) 0.95 0.51 0.88 (0.33-2.32) 0.80 0.52
AZGP1 nuclear 4.57 (0.55-38.01) 0.12 0.65 0.86 (0.35-2.12) 0.75 0.52
BTG2 1.25 (0.28-5.58) 0.77 0.53 0.79 (0.30-2.07) 0.63 0.53
CBX2 - 0.15 0.61 1.12 (0.37-3.37) 0.84 0.51
CNTNAP2 5.70 (1.27-25.57) 0.01 0.66 1.34 (0.39-4.62) 0.65 0.52
NME5 0.37 (0.045-3.11) 0.34 0.58 0.58 (0.19-1.75) 0.33 0.56
S100A8 0.35 (0.043-2.95) 0.32 0.59 0.10 (0.014-0.76) 0.01 0.65
SCUBE2 - 0.090 0.65 1.25 (0.47-3.33) 0.65 0.53
SERPINA11 2.23 (0.50-9.99) 0.28 0.60 0.98 (0.39-2.50) 0.97 0.50
STC2 0.17 (0.023-1.71) 0.10 0.68 0.68 (0.27-1.69) 0.40 0.55
STK32B 0.31 (0.037-2.54) 0.25 0.61 0.47 (0.16-1.41) 0.17 0.58
SUSD3 1.60 (0.31-8.26) 0.57 0.55 0.54 (0.22-1.34) 0.18 0.58
UBE2C 2.56 (0.49-13.28) 0.25 0.57 2.49 (0.88-7.01) 0.074 0.57
WHSC1L1 0.86 (0.10-7.16) 0.89 0.51 1.18 (0.27-5.10) 0.83 0.51
Multivariate analysis
Disease-specific survival Overall survival
HR (95% CI) p-value C-index HR (95% CI) p-value C-index
CNTNAP2 † 3.56 (0.78-16.17) 0.10 0.95 - - -
S100A8 ‡ -- - 0.11 (0.013-0.92) 0.01 0.83
Abbreviations: OSCC oral squamous cell carcinoma, HR hazard ratio, CI confidence interval, C-index concordance index.
Statistically significant data (p < 0.05) indicated with bold text.
† Adjusted for node status and tumor size.
‡ Adjusted for node status, tumor size, differentiation, and age.
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improved by including the protein in a model containing
lymph node status and tumor size. These results show the
profound effect node metastases have on clinical outcome.
In future studies, it will be necessary to alter the study de-
sign to test the prognostic potential of CNTNAP2 fur-
ther, e.g. using a larger cohort containing node-negative
patients. Furthermore, the S100A8 gene, also known as
MRP-8 or calgranulin A, has been studied extensively in
head and neck cancer. Inclusion of S100A8 protein ex-
pression patterns in multivariate models together with
tumor size, node status, and age significantly improved
OS prediction. In addition, we found an association be-
tween low S100A8 levels (mRNA levels in Cohort II and
protein levels in Cohort III) and tumor differentiation.
S100A8 belongs to the S100 gene family, several of
which form a gene cluster on chromosome 1q21 and
are commonly induced by chronic and acute inflam-
mation [46-48]. In the present study, positive S100A8
immunostaining was also observed in a peritumoral in-
flammatory cell population, albeit similar in both S100A8-
positive and negative tumors. Overexpression of the
S100A8 protein has been observed in breast, colorec-
tal, gastric, lung, pancreatic, and prostate cancer, wheras
underexpression has been shown in various squamous cell
carcinomas of the head and neck [49]. Recently, the
S100A8/A9 heterocomplex was identified as a regulator of
cell cycle progression and cell proliferation in cancer cell
lines originating from the head and neck region [50].
OSCC outcome prediction may also be improved by
identifying biomarkers that can predict which tumors
will inevitabily spread to the cervical nodes. When we
initiated this study, we believed that the CNTNAP2 gene
would be a strong candidate for lymph node status be-
cause of its association with metastatic spread to the ax-
illary lymph nodes in breast carcinoma [23]. However in
the present study, loss of SCUBE2 protein expression in
the tumor epithelial component was the only marker
significantly associated with lymph node status and bor-
derline significant for DSS. Interestingly, all 12 patients
with SCUBE2-positive tumors were long-term disease-
specific survivors and only 1/12 tumors had metasta-
sized to the cervical lymph nodes.These findings are
consistent with reports in breast carcinoma where ele-
vated levels of the SCUBE2 protein not only inhibited
proliferation of breast cancer cell lines, but was indica-
tive of a more favorable prognosis [23,51]. SCUBE2 is a
multidomain, secreted glycoprotein that was first impli-
cated in functioning upstream of hedgehog signaling in
zebrafish, but has since been shown to also play a pivotal
role in human tumorigenesis [52,53]. Furthermore,
SCUBE2 serves two different functions by using either
the CUB domain at the C-terminal end or the EGF-like
repeats at the N-terminus, i.e. control of cell proliferation
by antagonizing bone morphogenetic protein (BMP) activ-
ity and regulation of cell-cell contacts, and possibly tumor
metastasis, by forming complexes with E-cadherin in
adherens junctions, respectively [54].
The role CBX2 and STK32B play in OSCC tumorigen-
esis is largely unknown. In a correlation analysis between
protein expression patterns and established clinicopatho-
logical features, a clear link was found between CBX2-
positivity and tumor inflammatory infiltration as well as
STK32B-positivity and small tumor size (T1-T2). CBX2
plays a role in epigenetic regulation and hematopoietic
stem cell differentiation, whereas the STK32B gene is
one of several serine/threonine kinases (STK32B, STK36,
and STK39) with similar gene expression patterns in
basal-like breast cancers [16,55,56]. Consequently, STK36
is a component of the hedgehog signaling pathway. The
function of the STK32B gene is not known, but single
nucleotide polymorphisms in the STK32B gene have
been associated with oral clefts [57].
Hedgehog signaling has also been implicated in OSCC
and basal cell carcinoma, a skin cancer frequently found
in the head and neck region [58,59]. Leovic and col-
leagues illustrated the clinical relevance and aberrant ex-
pression of key hedgehog signaling components in SCCs
of the oral cavity and oropharynx, i.e. PTCH1, GLI1,
SMO, and SHH [58]. In Cohort II, several genes which
play a role in hedgehog signaling were also found to be
associated with high histological grade (the KIF7, TCTN1,
and TCTN2 genes) and metastatic spread to the cervical
lymph nodes (the FGF4 and PTCHD1 genes). These find-
ings further emphasize the importance of hedgehog sig-
naling in OSCC.
Conclusions
In summary, our results illustrate that cancer is a com-
plex, heterogeneous disease. However, certain clinically
relevant biomarkers may be useful therapeutic targets
for several different cancer types. Despite the limited
number of patients included in the study, the integrative
analysis identified at least five of the putative biomarkers
originally developed in breast carcinoma (CBX2, CNTNAP2,
S100A8, SCUBE2, and STK32B) that also improve risk as-
sessment for OSCC patients and may play a crucial role in
cancer-related processes, e.g. hedgehog signaling, regulation
of cell cycle progression, cell proliferation, metastasis. These
targets should be studied in a larger cohort to further evalu-
ate their clinical significance in OSCC.
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